KRAS mutations are primary genetic lesions leading to pancreatic cancer. The promoter of human KRAS contains a nuclease-hypersensitive element (NHE) that can fold in G4-DNA structures binding to nuclear proteins, including MAZ (myc-associated zinc-finger). Here, we report that MAZ activates KRAS transcription. To knockdown oncogenic KRAS in pancreatic cancer cells, we designed oligonucleotides that mimic one of the G-quadruplexes formed by NHE (G4-decoys). To increase their nuclease resistance, two locked nucleic acid (LNA) modifications were introduced at the 3'-end, whereas to enhance the folding and stability, two polycyclic aromatic hydrocarbon units (TINA or AMANY) were inserted internally, to cap the quadruplex. The most active G4-dec...
KRAS is a well-validated anti-cancer therapeutic target, whose transcriptional downregulation has be...
DNA G-quadruplexes (G4s) form in relevant genomic regions and intervene in several biological proces...
Mutated KRAS protein is a pivotal tumor driver in pancreatic cancer. However, despite comprehensive ...
MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications s...
KRAS is mutated in >90% of pancreatic ductal adenocarcinomas. As its inactivation leads to tumour re...
The oncogene KRAS is involved in the pathogenesis of many tumors such as pancreatic, lung and colore...
KRAS is a GTPase involved in the proliferation signaling of several growth factors. The KRAS gene is...
Non-canonical base pairing within guanine-rich DNA and RNA sequences can produce G-quartets, whose s...
KRAS is one of the most mutated genes in human cancer. Its crucial role in the tumourigenesis of pan...
In a previous study we have demonstrated that two neighboring G-quadruplexes, hras-1 and hras-2, loc...
The human KRAS proto-oncogene contains a critical nuclease hypersensitive element (NHE) upstream of ...
The ras genes are promising therapeutic targets in anticancer strategies. Somatic mutations on the g...
The human KRAS transcript contains a G-rich 5\ue2\u80\ub2-UTR sequence (77% GC) harboring several G4...
The role of G-quadruplexes (G4) which can coexist with canonical duplex DNA in the human genome is s...
In a previous study we have demonstrated that two neighboring G-quadruplexes, <i>hras</i>-1 and <i>h...
KRAS is a well-validated anti-cancer therapeutic target, whose transcriptional downregulation has be...
DNA G-quadruplexes (G4s) form in relevant genomic regions and intervene in several biological proces...
Mutated KRAS protein is a pivotal tumor driver in pancreatic cancer. However, despite comprehensive ...
MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications s...
KRAS is mutated in >90% of pancreatic ductal adenocarcinomas. As its inactivation leads to tumour re...
The oncogene KRAS is involved in the pathogenesis of many tumors such as pancreatic, lung and colore...
KRAS is a GTPase involved in the proliferation signaling of several growth factors. The KRAS gene is...
Non-canonical base pairing within guanine-rich DNA and RNA sequences can produce G-quartets, whose s...
KRAS is one of the most mutated genes in human cancer. Its crucial role in the tumourigenesis of pan...
In a previous study we have demonstrated that two neighboring G-quadruplexes, hras-1 and hras-2, loc...
The human KRAS proto-oncogene contains a critical nuclease hypersensitive element (NHE) upstream of ...
The ras genes are promising therapeutic targets in anticancer strategies. Somatic mutations on the g...
The human KRAS transcript contains a G-rich 5\ue2\u80\ub2-UTR sequence (77% GC) harboring several G4...
The role of G-quadruplexes (G4) which can coexist with canonical duplex DNA in the human genome is s...
In a previous study we have demonstrated that two neighboring G-quadruplexes, <i>hras</i>-1 and <i>h...
KRAS is a well-validated anti-cancer therapeutic target, whose transcriptional downregulation has be...
DNA G-quadruplexes (G4s) form in relevant genomic regions and intervene in several biological proces...
Mutated KRAS protein is a pivotal tumor driver in pancreatic cancer. However, despite comprehensive ...